AUTOTAC Bio
The original 2022 study demonstrated the p62-mediated AUTOTAC platform. A 2026 investigator conference abstract still describes IND-enabling preclinical work in neurodegenerative disease.
South KoreaFull profile →
Find your next research lead.
All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
471 company identities · 13 technology & service fields
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
5 matching companies
Origami Therapeutics
The website describes ORICISION as discovering both protein degraders and conformational correctors, emphasizing patient-derived models and clearance of disease-associated proteins.
United StatesFull profile →
Dunad Therapeutics
The current website focuses on covalent chemistry and ALS / Parkinson's programs. An original 2021 announcement records a four-target Novartis collaboration.
United KingdomFull profile →
TRIMTECH Therapeutics
A 2026-06-23 announcement states that TRIM21 E3-associated TRIMTAC/TRIMGLUE selectively degrade toxic aggregates and oligomers while sparing functional monomers, in early portfolio development.
United KingdomFull profile →
Dyne Therapeutics
Dyne describes its FORCE platform as a transferrin-receptor-binding Fab, linker, and therapeutic payload for muscle and CNS delivery. Oligonucleotide conjugation and candidate-specific clinical results should be assessed separately.
Coverage expands from sourced records; this database does not claim all biopharma companies.